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Live-attenuated influenza virus (LAIV) prime-boost vaccination previously conferred protection against
heterologous H3N2 swine influenza challenge, including in piglets with maternally derived antibodies
(MDA). Conversely, a whole-inactivated virus (WIV) vaccine was associated with enhanced disease. This
study was aimed at identifying immune correlates of cross-protection. Piglets with and without MDA received
intramuscular adjuvanted WIV or intranasal LAIV, and were challenged with heterologous H3N2. WIV
induced cross-reactive IgG, inhibited by MDA, and a moderate T cell response. LAIV elicited mucosal
antibodies and T cells cross-reactive to the heterologous challenge strain. The presence of MDA at LAIV
vaccination blocked lung and nasal antibody production, but did not interfere with T cell priming. Even
without mucosal antibodies, MDA-positive LAIV vaccinates were protected, indicating a likely role for T cells.
Based on the data, one LAIV dose can induce cell-mediated immunity against antigenically divergent H3N2
influenza virus despite passive antibody interference with humoral immune responses.
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a b s t r a c t
Live-attenuated inﬂuenza virus (LAIV) prime-boost vaccination previously conferred protection against
heterologous H3N2 swine inﬂuenza challenge, including in piglets with maternally derived antibodies
(MDA). Conversely, a whole-inactivated virus (WIV) vaccine was associated with enhanced disease. This
study was aimed at identifying immune correlates of cross-protection. Piglets with and without MDA
received intramuscular adjuvanted WIV or intranasal LAIV, and were challenged with heterologous
H3N2. WIV induced cross-reactive IgG, inhibited by MDA, and a moderate T cell response. LAIV elicited
mucosal antibodies and T cells cross-reactive to the heterologous challenge strain. The presence of MDA
at LAIV vaccination blocked lung and nasal antibody production, but did not interfere with T cell priming.
Even without mucosal antibodies, MDA-positive LAIV vaccinates were protected, indicating a likely role
for T cells. Based on the data, one LAIV dose can induce cell-mediated immunity against antigenically
divergent H3N2 inﬂuenza virus despite passive antibody interference with humoral immune responses.
Published by Elsevier Inc.
Introduction
Swine inﬂuenza A virus (IAV) vaccines are commonly adminis-
tered in commercial herds, but multiple factors hinder their
success in controlling inﬂuenza outbreaks. Vaccines containing
whole-inactivated virus (WIV) antigens elicit neutralizing antibo-
dies to antigenically similar strains and confer protection against
homologous challenge (Bikour et al., 1996; Van Reeth et al., 2001).
However, IAV strains with even a few mutations in the viral
surface proteins can evade neutralization (Jin et al., 2005). Anti-
genic evolution frequently leads to evasion of pigs' WIV-induced
immunity (Lee et al., 2007; Van Reeth et al., 2001; Vincent et al.,
2010). Furthermore, both HA subtypes of swine-lineage IAV (H1
and H3) include multiple co-circulating phylogenetic clusters,
which are antigenically distinct (Lorusso et al., 2010; Loving
et al., 2013; Nelson et al., 2012). Therefore, it is difﬁcult to maintain
well-matched IAV vaccines for swine (Ma and Richt, 2010).
Immunizing sows to stimulate colostrum-mediated passive transfer
of antibodies to their piglets is a common practice in the swine
industry. Passively acquired antibodies reduce infection and disease
with similar strains until antibody titers wane below a protective
threshold (Loeffen et al., 2003). However, maternally-derived anti-
bodies (MDA) can interfere with immune responses to vaccines
(Kitikoon et al., 2006).
Live-attenuated inﬂuenza virus (LAIV) vaccines delivered intra-
nasally have shown promise as a means to induce T cells and
mucosal immunity that cross-react with antigenically drifted and
heterosubtypic strains, both in pigs and humans (Hoft et al., 2011;
Masic et al., 2010). We previously reported protective immunity
against heterologous H3N2 and heterosubtypic H1N1 infections in
young pigs immunized with an experimental LAIV engineered to
express a truncated NS1 protein (Kappes et al., 2012; Vincent et al.,
2007). This LAIV vaccine, administered intranasally in two doses,
provided cross-protection even when administered to piglets with
high titers of homologous MDA (Vincent et al., 2012). This was in
marked contrast to a WIV vaccine that failed, and in fact exacer-
bated heterologous infection severity, when given to piglets with
maternal immunity. H3N2 LAIV induced humoral immunity such
that bronchoalveolar lavage (BAL) specimens contained signiﬁcant
levels of IgA and IgG with reactivity to the challenge strain,
although not in MDA-positive piglets (Vincent et al., 2012).
Determining correlates of cross-protective immunity could facil-
itate improved regulatory evaluation of commercial LAIV vaccines
since traditional serological parameters are not induced reliably by
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LAIV in swine or humans (Belshe et al., 2000; Loving et al., 2013).
No LAIV vaccines for swine inﬂuenza are currently licensed.
General requirements for approval of live vaccines, by regulatory
agencies such as the USDA Center for Veterinary Biologics, include
demonstrating efﬁcacy, safety in target and non-target host
species, stability of the attenuated phenotype, and an environ-
mental risk assessment (Rippke et al., 2012).
In the previous study that compared H3N2 WIV and LAIV
vaccines, MDA(þ) piglets vaccinated with the adjuvanted WIV
and challenged with an antigenically divergent H3N2 IAV strain
developed more severe respiratory tract lesions than non-
vaccinated controls (Vincent et al., 2012). The adverse outcome in
WIV vaccinates was similar to the vaccine-associated enhanced
respiratory disease (VAERD) phenomenon described in pigs that
were vaccinated with an H1N2 WIV and challenged with hetero-
logous H1N1 (Gauger et al., 2012, 2011), except that MDA were not
involved in the H1-subtype VAERD pathogenesis. Both the H3 and
H1 models of VAERD are characterized by increased percentages of
macroscopic pneumonia with severe bronchointerstitial pneumo-
nia, necrotizing bronchiolitis, and interlobular and alveolar edema
and hemorrhage (Gauger et al., 2012; Vincent et al., 2012). IAV-
speciﬁc IgG antibodies that fail to neutralize the challenge virus are
likely involved in VAERD pathogenesis (Khurana et al., 2013). High
levels of virus-binding IgG were detected in lungs of pigs affected by
H3N2 VAERD, 5 days post-infection. The mechanism by which non-
neutralizing antibodies might promote inﬂammation and the pos-
sible involvement of vaccine-primed B and T cells has not been
resolved.
Objectives of this study included testing the efﬁcacy of a single
dose LAIV regimen in piglets with and without MDA; determining
the effects of MDA on cellular and mucosal immune responses;
and identifying immune responses correlated with VAERD versus
cross-protection upon heterologous challenge.
Results
Serological response to vaccines
Immunization of sows with multiple doses of TX98 WIV
vaccine elicited homologous serum HI antibody titers of 160 or
greater. Non-vaccinated sows had HI titers r20, and were also
seronegative by nucleoprotein-speciﬁc commercial ELISA (Ciacci-
Zanella et al., 2010). Neonatal piglets from the vaccinated sows
acquired passive HI antibody at similar high titers, which waned
steadily (Fig. 1A). There was very limited HI cross-reactivity to the
challenge strain, CO99 (Fig. 1B), consistent with previous studies
(Richt et al., 2003; Vincent et al., 2012). Piglets were vaccinated
with WIV or LAIV at weaning. Serum HI antibody responses to
both vaccines were low or below detection limits prior to
challenge (Fig. 1A). The WIV vaccine elicited IgG antibodies
detectable by ELISA, including moderate cross-reactivity with the
heterologous challenge strain (Fig. 1C and D).
Mucosal antibody response to vaccines
Subgroups of pigs were sacriﬁced at 0 dpi to analyze respira-
tory tract local immunity prior to infection. There was no evidence
of maternally derived IAV-speciﬁc IgA in BAL samples of non-
vaccinated (NV) piglets 7–8 weeks of age (Fig. 2A and B). In MDA
() piglets, a single LAIV dose elicited a strong IgA response, and
these antibodies cross-reacted with CO99. In contrast, no BAL IgA
response was detected in animals given two doses of WIV. In MDA
(þ) piglets, the BAL IgA response to LAIV was inhibited. With
regard to IAV-speciﬁc IgG, passive maternal antibodies remained
in lungs of NV pigs at moderate levels, 7–8 weeks after piglets had
ingested colostrum (Fig. 2C and D). LAIV induced the highest BAL
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Fig. 1. Serum antibody levels due to maternally derived antibodies and responses to vaccination. Reciprocal geometric mean HI titers against TX98 H3N2 antigen (A) and
CO99 antigen (B) are shown for time points prior to and after challenge. MDA(þ) pigs were from sows immunized with the TX98 WIV vaccine. Treatment groups were non-
vaccinated (NV), vaccinated I.M. at 0 dpv and 14 dpv with TX98 WIV, vaccinated I.N. with TX98 LAIV at 0 dpv only (LAIVx1), or vaccinated I.N. with LAIV at 0 dpv and 14 dpv
(LAIVx2). IgG antibodies binding to TX98 (C) and CO99 (D) whole viral antigens were measured by ELISA in 34 dpv sera. Open bars designate groups without MDA, and solid
bars designate groups with MDA. Statistically signiﬁcant differences between MDA statuses within a vaccine group are marked with asterisks, and differences between
vaccine treatment groups with matched MDA statuses are identiﬁed by connecting lines (Po0.05).
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IAV-speciﬁc IgG response in MDA() groups but, like the IgA
isotype, this was inhibited by MDA. WIV immunization induced
moderate IAV-speciﬁc BAL IgG; this was also reduced in MDA(þ)
piglets, although the difference was not statistically signiﬁcant
from MDA() pigs.
IAV-speciﬁc IgA levels were also measured in nasal wash (NW)
specimens collected at 1 dpi from the same piglets. Although the
magnitude of IgA signal was lower in NW, the pattern of results
approximately mirrored results from 0 dpi BAL samples. Among
MDA-negative piglets, LAIV vaccinates had signiﬁcantly more
TX98-binding IgA than WIV vaccinates (Fig. 2E and F). The
presence of MDA at vaccination blocked NW IgA responses to
LAIV. Overall, results from pre-challenge samples indicate that
LAIV vaccination induced a robust local antibody response in the
respiratory tract, while WIV vaccinees developed moderate quan-
tities of lung IgG only, but the presence of MDA at vaccination
suppressed humoral responses to both vaccines.
Cellular immune response to vaccines
T cell priming was analyzed by testing ex vivo recall responses
to homologous and heterologous H3N2 strains. Based on expres-
sion of CD25, IFN-γ, and IL-10, peripheral blood CD4þCD8þ
T cells were primed by WIV and LAIV vaccines (Fig. 3). In terms
of surface CD25 expression after homologous TX98 stimulation,
the CD4þCD8þ cells showed extensive group-to-group variation
(Fig. 3A). The two treatment groups for which the CD25 marker
was signiﬁcantly upregulated compared to NV controls were MDA()
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Fig. 2. Respiratory mucosal antibody levels induced upon vaccination with WIV or LAIV. Nasal wash (NW) and bronchoalveolar lavage ﬂuid (BAL) specimens were collected
1 day before challenge infection (34 dpv, 1 dpi). Mean O.D. values in whole-virus ELISAs are shown for NW IgA antibodies against homologous TX98 (A) and heterologous
CO99 (B), BAL IgA antibodies against TX98 (C) and CO99 (D), and BAL IgG antibodies against TX98 (E) and CO99 (F). Open bars designate groups without MDA and solid bars
designate groups with MDA. Statistically signiﬁcant differences between vaccine treatment groups with matched MDA status are identiﬁed by connecting lines (Po0.05).
Signiﬁcant differences between MDA() and MDA(þ) groups receiving the same vaccine treatment are denoted with asterisks (Po0.05).
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WIV and MDA(þ) LAIVx2. Although CD25 recall responses varied in
the MDA(þ) LAIVx2 group, the mean was signiﬁcantly higher than in
either the MDA(þ) group receiving a single dose or the MDA()
group with two doses. In contrast, WIV vaccination only primed
CD4þCD8þ cells for signiﬁcant CD25 responses if administered to
MDA() piglets. Similar patterns were present in CD25 data from cells
stimulated with heterologous CO99 virus, including signiﬁcant recall
responses in MDA(þ) LAIVx2 piglets (Fig. 3B).
Like the CD25 marker, statistically signiﬁcant IFN-γ recall
responses were detectable in CD4þCD8þ cells from MDA(þ)
LAIVx2 vaccinees, after TX98 or CO99 stimulation (Fig. 3C and D).
There was evidence of IFN-γ recall responses in WIV-vaccinated
groups, although not statistically different from non-vaccinates.
The third recall marker, IL-10, indicated statistically signiﬁcant
responses for the MDA() WIV and MDA(þ) LAIVx2 groups, to
both strains (Fig. 3E and F), which closely mirrored the CD25
responses. The same recall response markers were simultaneously
analyzed in CD4þCD8 , CD4CD8þ , and γδ TCRþ peripheral
blood lymphocyte populations. In these populations, none of the
vaccine treatment groups showed statistically signiﬁcant responses
to the homologous TX98 strain (Supplemental Fig. S1) or hetero-
logous CO99 (data not shown).
ELISpot results from virus-stimulated PBMC (Fig. 4A and B)
were consistent with the ﬂow cytometry-based intracellular IFN-γ
data described above. Notably, IAV-speciﬁc IFN-γ SCs were
detected with the highest frequencies in the MDA(þ) LAIVx2
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Fig. 3. Vaccine priming of T cells for IAV-speciﬁc upregulated expression of surface CD25 and intracellular IFN-γ and IL-10. PBMC isolated from pigs 28 dpv were cultured
ex vivo for 4 days in the presence of TX98, CO99, or no virus. Response markers and subset markers were analyzed by multi-parameter ﬂow cytometry. For each T-cell subset
there are paired graphs representing responses to TX98 (vaccine strain) or CO99 (challenge strain). The mean virus-speciﬁc increase in percentage of cells expressing a
response marker is plotted on the y-axis. Open bars represent MDA() pigs, and ﬁlled bars represent MDA(þ) pigs. Error bars represent standard error of the mean.
Statistically signiﬁcant differences between vaccine treatment groups with matched MDA status are identiﬁed by connecting lines (Po0.05). Signiﬁcant differences between
MDA() and MDA(þ) groups receiving the same vaccine treatment are denoted with asterisks (Po0.05).
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treatment group. TBLN cells were also isolated from subgroups of
NV, WIV, and LAIVx1 vaccinated pigs that were euthanized before
challenge infection (35 dpv/0 dpi). Modest numbers of IFN-γ
secreting cells were detected in TBLN cells stimulated with either
TX98 or CO99 from WIV-vaccinated pigs (Fig. 4C and D). Greater
numbers of IFN-γ SCs were detected from TBLN of the LAIVx1
groups, and the numbers of LAIV-induced IFN-γ SCs were greater
in the TBLN than in PBMC (TBLN were not obtained from LAIVx2
vaccinated pigs). Signiﬁcant differences in TBLN T cell recall
responses between MDA() and MDA(þ) pigs were not detected.
Vaccine efﬁcacy against heterologous challenge
Virus shedding from the nasal cavity was limited during the
challenge experiment, as virus was detected in 3 of 8 MDA() NV
pigs, 8 of 8 MDA(þ) NV pigs, 4 of 8 MDA() WIV pigs, 7 of 8 MDA(þ)
WIV pigs, 0 of 8 MDA() LAIVx1 pigs, 5 of 8 MDA(þ) LAIVx1 pigs,
0 of 8 MDA() LAIVx2 pigs, and 2 of 8 MDA(þ) LAIVx2 pigs (data not
shown). All positive nasal swabs had titers below 103 TCID50/ml. In
lungs, the challenge virus replicated more extensively, based on 5 dpi
BAL infectivity titers (Fig. 5A) and viral antigen detection in lung tissue
(Fig. 5B). None of the LAIV-vaccinated pigs had detectable viable virus
in BAL or IAV antigen in lung tissue. Among MDA() WIV-vaccinated
pigs there was very little infectious virus in 5 dpi BAL, yet the amount
of viral antigen detected in the lung tissues by IHC was as high as in
NV animals. WIV vaccination had little effect in reducing lung viral
load when administered to MDA(þ) animals (Fig. 5A).
Composite clinical scores peaked about 3–4 dpi, with disease
most severe in WIV-vaccinated groups (Fig. 5C). The NV groups
both had mild clinical disease, while in the LAIV-vaccinated groups
almost no clinical signs were observed. Mean rectal temperatures
were similar until 5 dpi, when mean temperatures of the MDA(þ)
NV and MDA(þ) WIV groups surpassed 40.5 1C, whereas equiva-
lent MDA() groups approached the normal baseline near 39.5 1C.
WIV vaccination exacerbated the clinical severity of heterologous
infection, while LAIV was cross-protective.
WIV-vaccinated piglets had higher macroscopic lung lesion
scores than NV counterparts of matching MDA status (Fig. 5E). The
mean percentage of lung area affected with pneumonia was 26.6%
in the MDA() WIV group and 17.1% in the MDA(þ) WIV group as
compared to the MDA() NV control group at 10.5%. Piglets in
LAIV-vaccinated groups showed no evidence of macroscopic
pneumonia, regardless of MDA status or the number of LAIV doses
received. Microscopic lesions of lung tissues were most pro-
nounced in the WIV-vaccinated groups, whereas LAIV-vaccinated
groups had the lowest scores (Fig. 5F and G). Tracheal microscopic
lesion scores were signiﬁcantly greater in WIV-vaccinated groups
than LAIV groups, with trends similar to microscopic lung injury.
Overall, analysis of respiratory tract pathological lesions shows a
similar pattern to clinical disease scores, pointing to exacerbation
by WIV, cross-protection by LAIV, and no major impact by the
presence of MDA at vaccination.
Post-challenge lung immune responses
At necropsy (5 dpi), post-challenge BAL TX98- and CO99-
binding IgG were present at higher levels (Fig. 6) compared to
the pre-challenge levels (Fig. 2), indicating a local response
induced by infection. Similarly, IAV-speciﬁc IgA reached higher
levels in 5 dpi BAL than in equivalent 0 dpi samples. MDA() LAIV
vaccinees continued to have the highest levels of IAV-speciﬁc IgA
at 5 dpi. In all cases, the presence of MDA at the time of
vaccination diminished the local antibody response to challenge.
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Fig. 4. Vaccine priming of IAV-speciﬁc T cells in lung-draining lymph nodes. TBLN cells were harvested from non-infected pigs that were sacriﬁced 35 dpv, and tested by IFN-γ
ELISpot for responses to TX98 and CO99. The mean number of spot-forming cells in duplicate wells is plotted for each pig, and the treatment group means and standard errors of
the means are denoted with bars. Statistically signiﬁcant differences between vaccine treatment groups with matched MDA status are identiﬁed by connecting lines (Po0.05).
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Discussion
H3N2 strains of several antigenically distinct lineages circulate
in swine (Vincent et al., 2014). The diversity and rapid evolution of
these viruses impairs efﬁcacy of commercial vaccines containing
WIV antigens (Ma and Richt, 2010). Sows are commonly immu-
nized with WIV vaccines to enable colostrum-mediated protection
of young piglets, although MDA can interfere with immunization
of the young pigs (Kitikoon et al., 2006; Loeffen et al., 2003). Our
previous study tested immune responses and cross-protective
efﬁcacy of H3N2 WIV versus LAIV (Vincent et al., 2012). Both
vaccines conferred protection against homologous challenge, but
in MDA(þ) animals the outcomes of heterologous H3N2 challenge
were markedly different. LAIV provided moderate cross-protec-
tion, even in MDA(þ) pigs. WIV vaccination in MDA(þ) animals
failed to limit viral replication and it led to more severe respiratory
tract lesions, i.e. VAERD. The adverse outcome was associated with
the presence of virus-binding IgG that lacked HI cross-reactivity,
which was also observed in an H1N1 model of VAERD (Gauger
et al., 2011). The present study was aimed at identifying immune
parameters associated with cross-protection versus disease
enhancement following heterologous challenge.
LAIV vaccination conferred signiﬁcant cross-protection against
the heterologous CO99 virus challenge. Regardless of the dose
Fig. 5. Viral replication, disease, and respiratory tract tissue damage after heterologous H3N2 challenge. Groups of pigs, with and without MDA, received no vaccine (NV),
two I.M. doses of TX98 WIV, one I.N. dose of TX98 LAIV, or two I.N. doses of LAIV. 35 days after the initial vaccine dose, piglets were challenged by I.T. inoculation with CO99.
(A) BAL specimens were collected at necropsy (5 dpi) and titrated by TCID50 assay on MDCK cells. (B) Lung tissue sections were stained for IAV antigen by IHC. Clinical disease
scores (C) and rectal temperatures (D) were monitored daily. Lungs were evaluated for macroscopic pneumonia (E) and microscopic pneumonia (F). Tracheal tissue was
evaluated for microscopic lesions (G). Open bars and symbols represent MDA() groups, and ﬁlled bars and symbols represent MDA(þ) groups. Error bars indicate standard
errors of the means.
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regimen (1 or 2 doses) or the MDA status at vaccination, LAIV
protected pigs from clinical disease, lung lesions, and viral load in the
airways. In contrast, WIV-vaccinated groups displayed enhanced
clinical disease and developed more severe respiratory tract lesions
than NV controls, results that are consistent with the H3N2 VAERD
reported previously (Vincent et al., 2012). In the prior study, VAERD
occurred only in pigs that had receivedWIV vaccination in the face of
MDA. In the current study, we observed no increased propensity for
VAERD in the MDA(þ) pigs. This variation might be explained by
considering the levels of functional cross-reactive antibodies to the
CO99 challenge strain remaining at challenge. In the previous study,
WIV vaccination induced robust HI titers in MDA() piglets with
low cross-reactive HI activity against CO99 challenge virus, likely
reducing disease severity. In the current study, MDA() WIV-
vaccinated piglets had lower homologous HI titers and developed
no detectable serum cross-reactive HI activity against CO99, likely
leaving them susceptible to VAERD pathogenesis. Another difference
between the two studies was in the delivery and dose of challenge
virus. The CO99 inoculum titer was 20-fold less in the current study
(103.7 TCID50/ml compared with 105 TCID50/ml) and was adminis-
tered to non-anesthetized pigs, potentially allowing pigs to cough
and dispel virus after its placement in the trachea. These results
again emphasize the marked difference in efﬁcacy between LAIV and
WIV vaccines and the complexity of vaccination of pigs with variable
immune statuses.
LAIV vaccines for swine IAV have been shown, in seronegative
pigs, to elicit lung mucosal antibodies (Masic et al., 2010; Vincent
et al., 2012). Similarly, naïve infants vaccinated with trivalent LAIV
for seasonal inﬂuenza developed increased IgA levels, which were
associated with a lower rate of culture-conﬁrmed inﬂuenza illness
(Ambrose et al., 2012). In the present study, vaccine-induced
mucosal immunity was analyzed by measuring virus-binding IgA
and IgG in upper and lower respiratory tract samples collected
before challenge. Most LAIV vaccinated pigs developed mucosal
IgA in both locations; however, IAV-speciﬁc IgG was only detected
in the lower respiratory tract. In comparison, the WIV vaccine
elicited moderate lung IgG responses before challenge but no
mucosal IgA. Overall, local IgA and IgG cross-reacted with CO99
challenge virus. These ﬁndings agree with the concept that
intranasally administered LAIV vaccines elicit superior mucosal
antibody responses (Cheng et al., 2013). Cross-reactive mucosal
antibodies in MDA() LAIV vaccinated pigs may have been
sufﬁcient to block infection without requiring full recruitment
and activation of memory T cells. We hypothesized that intranasal
LAIV would induce a mucosal antibody response even in pigs with
circulating MDA. In fact, MDA(þ) pigs had almost no local IgA and
IgG responses to either vaccine. This suggests it could be difﬁcult
to use nasal IgA as a correlate of LAIV vaccine-induced immunity
in ﬁeld studies where many young pigs would have MDA from
their vaccinated or exposed mothers.
Lower respiratory tract samples from infected pigs (5 dpi) were
also assayed for IAV-speciﬁc antibodies, which transudated into
the lungs or were produced by local B cells during infection.
Vaccinated groups, particularly LAIV vaccinates, had increased BAL
IgA and IgG levels after infection. Groups that were vaccinated in
the face of MDA continued to have reduced levels of IAV-speciﬁc
lung antibodies after challenge. Based on mucosal antibody levels
only, one might predict MDA(þ) LAIV vaccinees to be vulnerable
to infection; however they were protected against heterologous
challenge. This suggests that B cells were able, possibly with the
aid of memory T helper cells, to mount an anamnestic antibody
response early in infection (note the rapid rise in antibodies
(Fig. 1B)), and/or that T cells provided robust protection.
Previous studies showed LAIV induction of T cells in MDA()
pigs and in humans (Chirkova et al., 2011; He et al., 2006; Hoft
et al., 2011; Lanthier et al., 2011; Loving et al., 2012; Masic et al.,
2010). Porcine T cells can be differentiated into four major subsets
based on surface phenotype markers: CD4þCD8 , CD4CD8þ ,
CD4þCD8þ (expressing CD8α chain only), and γδ TCRþ . In the
present study, cellular immune responses were analyzed by ex vivo
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Fig. 6. Antibody levels in BAL at 5 days post-infection with heterologous CO99. Mean O.D. values in whole-virus ELISAs are shown for IgA antibodies against TX98 (A) and
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antigenic stimulation of T cells from the peripheral blood and
draining lymph nodes (TBLN). T cell responses from PBMC and TBLN
were generally equivalent to heterologous CO99 virus and homolo-
gous TX98 virus (Figs. 3 and S1), which supports the concept that the
cellular immune response is more broadly reactive than serum HI
antibodies. The T cell subset with the most signiﬁcant responses to
viral stimulation was the CD4þCD8þpopulation, which exist outside
the thymus in pigs (Saalmuller et al., 1987). Porcine CD4þCD8þ cells
have been characterized as memory cells with T helper function
(reviewed by Gerner et al. (2009)), which also can express perforin
and mediate cytolytic activity against virally infected cells (De Bruin
et al., 2000; Denyer et al., 2006). The porcine CD4þCD8þ population
was recently differentiated into CD27þ and CD27 subpopulations,
with phenotypes corresponding to central and effector memory cells,
respectively (Reutner et al., 2013). In the current study, priming of
CD4þCD8þ T cells was evident in both WIV and LAIV vaccinated
pigs, in terms of response markers CD25, IFN-γ, and IL-10 (Fig. 3). The
presence of MDA at vaccination had distinct effects on induction of
CD4þCD8þ T cell responses, depending on whether the vaccine was
WIV or LAIV, as there was evidence of a dampening effect onWIV and
an enhancing effect on LAIV. This could reﬂect differences in antigen
processing for the inactivated versus replicating antigens. The two
vaccines differ greatly in formulation and route of delivery, and
previous studies showed that modulatory effects of preexisting anti-
bodies can be either positive or negative, depending on factors such as
antigen concentration and engagement of alternate Fc receptors
(Crowe, 2001).
Between the treatment groups that received 1 or 2 doses of LAIV,
higher recall responses were observed in the peripheral T cells of the
groups receiving 2 doses. Presumably, the ﬁrst dose primed a small
population of cells, which expanded after the second dose. Even so,
IFN-γ responses were readily detected from the TBLN cells of single-
dose LAIV-vaccinated pigs. Data captured from the TBLN, which drain
the site of infection and intranasal LAIV vaccination, are a valuable
complement to data from peripheral blood cells. Both vaccines,
particularly LAIV, elicited effector or memory cells that were available
to respond to infection. Taken together, these data indicate that
cellular immunity induced by the LAIV vaccine was not impeded by
MDA or by the antigenic divergence between H3N2 strains. Cellular
immunity may have been the primary defense against heterologous
infection in the MDA(þ) LAIV group, which was deﬁcient in pre-
existing mucosal antibodies and serum HI antibodies.
Our data highlight the concept that LAIV vaccines confer broad
protection whether or not they induce detectable amounts of
systemic functional antibodies. In our model, LAIV-induced immu-
nity supplied multiple cross-reactive factors (mucosal antibodies and
T cells before infection and anamnestic systemic antibody response
after infection). When one factor was minimized (i.e. MDA inter-
ference with mucosal antibody induction), other mediators provided
cross-protection. On the other hand, our WIV primed an immune
response that had adverse effects to the host respiratory tract when
pigs were infected with a mismatched virus. These components
complicate the development of feasible antemortem correlates of
protection from either vaccine platform, and additional work is
required to deﬁne assays that can be applied in diagnostic settings.
However, the results are further evidence of the need for critical
review of WIV vaccination practices in sows and further develop-
ment of LAIV as an inﬂuenza vaccine platform for the swine industry.
Materials and methods
Viruses and vaccine preparation
Antigen for the WIV vaccine was wild type A/swine/Texas/
4199-2/1998 (H3N2) (TX98), grown in Madin-Darby canine kidney
(MDCK) cells or 9-day-old fertilized hen eggs. The WIV vaccine for
sows contained MDCK-grown virus, while the WIV vaccine for
piglets contained egg-grown virus. Clariﬁed virus supernatants
from infected culture were ultracentrifuged to pellet virus (2 h at
140,000g through a 25% sucrose cushion). Virus was resuspended
in PBS and UV-irradiated using the “sterilize” setting in a UV cross-
linking chamber (GS Gene Linker; Bio-Rad, Hercules, CA). Inactiva-
tion of the virus was conﬁrmed by two serial passages on MDCK
cells. A commercial adjuvant (Emulsigen D; MVP Laboratories, Inc.,
Ralston, NE) was added at a 1:4 volume ratio, bringing the ﬁnal
mixture to a hemagglutination (HA) titer of 128. The LAIV was
generated via reverse genetics as previously described (Solorzano
et al., 2005). The attenuated vaccine virus contained an NS1 gene
with a 30 premature termination, producing a protein of 126 amino
acids with a carboxy-terminal truncation (NS1Δ126 TX98). The
remaining seven gene segments were from wild-type TX98. The
challenge virus, A/sw/Colorado/23619/99 (H3N2) (CO99), was
cultivated in MDCK cells. The TX98 and CO99 viruses were shown
previously to have limited serologic cross-reactivity (Richt et al.,
2003) and therefore considered heterologous.
Experimental design
Sows at a high-health herd free of IAV and porcine reproductive
and respiratory syndrome virus (PRRSV) were vaccinated intra-
muscularly (neck) with the TX98 WIV in 3 doses, once before
breeding and twice during mid-late gestation. 2 weeks before
farrowing, vaccinated and non-vaccinated sows from the same
source were delivered to Veterinary Resources Inc. (VRI, Ames, IA),
which provided animal care and housing through the remainder of
the study. 1 week-old piglets were bled to evaluate transfer of
MDA and conﬁrm seronegative status of litters from non-
vaccinated sows. At 14–19 days of age piglets were weaned,
treated with ceftiofur crystalline-free acid (Excedes, Zoetis Inc.,
New York, NY), and randomly assigned to vaccine treatment
groups within the appropriate MDA status (Table 1). Initial doses
of WIV or LAIV were administered at 15–20 days of age. Piglets
were immunized with 2 ml of LAIV at 106 50% tissue culture
infective doses (TCID50) per ml intranasally or 2 ml WIV intra-
muscularly (neck). LAIV-vaccinated pigs were housed in separate
Table 1
Experimental treatment groups.
Treatment group MDA statusa Piglet vaccineb Challenge virus n
MDA() NV/NC  None Sham 4
MDA(þ) NV/NC þ None Sham 4
MDA() NV  None CO99c 8
MDA(þ) NV þ None CO99 8
MDA() WIV  WIV, 2 doses CO99 8
MDA(þ) WIV þ WIV, 2 doses CO99 8
MDA() LAIVx1  LAIV, 1 dose CO99 8
MDA(þ) LAIVx1 þ LAIV, 1 dose CO99 8
MDA() LAIVx2  LAIV, 2 doses CO99 8
MDA(þ) LAIVx2 þ LAIV, 2 doses CO99 8
MDA() NVn  None NCd 4
MDA(þ) NVn þ None NC 4
MDA() WIVn  WIV, 2 doses NC 8
MDA(þ) WIVn þ WIV, 2 doses NC 8
MDA() LAIVx1n  LAIV, 1 dose NC 8
MDA(þ) LAIVx1n þ LAIV, 1 dose NC 8
a MDA-positive pigs were from sows that had received 3 doses of TX98 WIV
vaccine. MDA-negative pigs were from non-vaccinated sows of the same
source farm.
b Vaccines are derived from A/Texas/4199-2/1998 (H3N2).
c A/swine/Colorado/23619/1999 (H3N2).
d NC, not challenged. Subgroups marked with asterisks were euthanized at 0 dpi
for pre-challenge specimens.
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rooms. Booster doses were administered 14 days later to the WIV
groups and designated LAIV groups. Extra groups of pigs in some
treatments were moved to separate housing at the USDA-ARS
National Animal Disease Center (Ames, IA) for collection of pre-
challenge specimens (Table 1). At 50–55 days of age [0 days post-
infection (dpi)], pigs were each inoculated intratracheally (2 ml)
and intranasally (1 ml) with virus suspension containing
103.7 TCID50/ml. Non-challenged control groups were housed in
separate isolation rooms. Pig studies at VRI and NADC were
conducted in compliance with their respective Institutional Animal
Care and Use Committees.
Clinical observation, sampling, and pathology
CO99 virus infected pigs were observed daily for clinical signs.
Three criteria (labored breathing, lethargy, and coughing) were
scored for severity on a scale of 1–4 and reported as a composite
clinical score. Rectal temperatures were recorded daily. Nasal
swabs were taken at 0, 1, 3, and 5 days postinfection (dpi), placed
in 2 ml minimal essential medium (MEM), and stored at 80 1C.
Animals were euthanized humanely at 5 dpi with a lethal dose of
pentobarbital. At necropsy, each lung was lavaged with 50 ml
MEM to obtain bronchoalveolar lavage ﬂuid (BAL). BAL samples
were conﬁrmed negative for nucleic acid of porcine circovirus 2,
PRRSV, and Mycoplasma hyopneumoniae, by quantitative PCR.
Nasal swabs were processed and analyzed by virus isolation as
described previously (Vincent et al., 2012). TCID50 virus titers in
BAL samples and each virus isolation-positive nasal swab sample
were determined as described previously (Vincent et al., 2012).
Macroscopic and microscopic lung lesions, and microscopic lesions
of trachea were analyzed and scored as described previously
(Gauger et al., 2012). IAV was detected in lung tissues by a
previously described immunohistochemical method (Braucher
et al., 2012).
Serologic and mucosal antibody assays
Serum samples were collected at pre-weaning (12 days post-
vaccination [dpv]), ﬁrst vaccination (0 dpv), second vaccination
(14 dpv), 27 dpv, 34 dpv, and 40 dpv (necropsy). For use in the
hemagglutination inhibition (HI) antibody assay, sera were treated
with receptor-destroying enzyme (Sigma-Aldrich, St. Louis, MO) to
remove nonspeciﬁc inhibitors and with turkey erythrocytes to
remove non-speciﬁc agglutinins and heat inactivated at 56 1C.
HI assays were performed with egg-grown TX98 and CO99 viral
antigens and turkey erythrocytes, using standard techniques
(Palmer et al., 1975). Enzyme-linked immunosorbent assays
(ELISA) to detect total IgG and IgA antibodies against whole virus
preparations of TX98 and CO99 present in serum and BAL were
performed as previously described (Gauger et al., 2011), with the
following modiﬁcations. Serum samples were diluted to 1:2000
for the IgG ELISA. BAL samples were diluted to 1:4 for IgG and IgA
ELISAs. Antibody levels were reported as the mean OD for
duplicate wells.
Multi-parameter ﬂow cytometry analysis of IAV-speciﬁc T cells
Peripheral blood mononuclear cells (PBMC) were stimulated by
ex vivo culture with virus and tested for response markers by
multi-parameter ﬂow cytometry, using a previously described
method (Platt et al., 2011). Brieﬂy, PBMC of each pig were
incubated for 4 days in the presence of TX98, CO99, or supernatant
of mock-infected MDCK cells. Antibodies to the CD4, CD8 and γδ
TCR markers were used with ﬂuorochrome-conjugated secondary
antibodies to label T cell subsets. The activation marker CD25 and
intracellular cytokines interferon-γ (IFN-γ) and interleukin-10
(IL-10) were labeled as measures of antigen-speciﬁc responses.
The net increase in the percentage of a subset to express each
response marker was calculated by subtracting the percentage of
mock-stimulated cells from that of virus-stimulated cells. If the net
result was negative, it was adjusted to 0.
ELISPOT analysis of IAV-speciﬁc T cells
Lymphocytes were dissociated from fresh tracheobronchial
lymph nodes (TBLN) by mechanical homogenization in 15 ml
plastic tissue grinder tubes (Kendall Healthcare Products). Follow-
ing homogenization, samples were run through a 40 mm ﬁlter
screen to eliminate debris. The cell suspension was overlayed onto
Histopaque 1077 gradient (Sigma-Aldrich) and buffy coats isolated.
Cells were washed twice, enumerated, and resuspended for seed-
ing into ELISpot plates. The ELISpot assay for IFN-γ secreting cells
(IFN-γ SCs) was performed as previously described (Braucher
et al., 2012) and according to the manufacturer's recommendation
(Porcine IFN-gamma ELISpot Kit, R&D Systems, Minneapolis, MN).
Brieﬂy, antibody-coated membrane plates were seeded with
5105 cells per well and stimulated with 0.1 ml of 5
106 TCID50/ml live TX98, CO99 virus, or uninfected MDCK culture
supernatant in triplicate. Following an 18–20 h incubation period,
plates were developed according to manufacturer's recommenda-
tions. Dry plates were scanned and analyzed with S5UV CTL-
ImmunoSpot instrumentation and software (Cellular Technology
Ltd., Shaker Heights, OH). Individual pig responses were calculated
as the average number of spots per triplicate well within a
stimulation treatment.
Statistical analysis
Macroscopic and microscopic pneumonia scores, log10-trans-
formed BAL and nasal swab virus titers, mean ODs for ELISAs, and
T-cell results (ﬂow cytometry and ELISpot) were analyzed using
analysis of variance (ANOVA) and the Tukey test for pairwise
comparisons between groups, with P valueso0.05 considered
signiﬁcant (Prism software; GraphPad, La Jolla, CA).
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